

GlcNAc is a Mast-cell Chromatin-remodeling Oncome


J. Agopian¹, Q. Da Costa¹, Q. Nguyen¹, G. Scorrano¹, A. Goubard¹, R. Castellano¹, P. de Sec JA Asara², O. Hermine³, P. Dubreuil¹, F. Brenet^{1*}

¹Cancer Research Center of Marseille (CRCM), France, ²BIDMC, Boston, USA, ³Imagine Institute, Pari

udy is to determine if potential for SM severity and regulate MCs









immunity but also in allergic reactions and asthma. activity of MCs are typical features), a myeloproliferative disorder MCs burden in organs leading to M ranges from indolent to severe, h limited therapeutic options; all mutation in the receptor tyrosine


SYSTEMIC MASTOCYTOSIS CLASSIFICATION





2/ GICNAC IS A CIRCULATING BIOMARKER OF SM SEVERITY





nflammation



Canceropole

ACKNOWLEDGMENTS

fabienne.brenet@inserm.fr